---
title: "Baxter International 2026: Revenue $2.96B, EPS $0.24— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294414777.md"
description: "Baxter International reported Q2 2026 revenue of $2.96B, up 5.3% YoY, and diluted EPS of $0.24, up 33.3%. Growth was driven by volume gains in Infusion Therapies and Advanced Surgery, which rose ~12%. The company reorganized into two segments and launched a new operating model. However, supply constraints and a Novum LVP distribution hold negatively impacted pump and injectables volumes."
datetime: "2026-07-30T20:51:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294414777.md)
  - [en](https://longbridge.com/en/news/294414777.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294414777.md)
---

# Baxter International 2026: Revenue $2.96B, EPS $0.24— 10-Q Summary

Baxter International reported second-quarter 2026 results showing revenue growth and higher earnings versus the year-ago quarter, supported by volume gains in Infusion Therapies and Advanced Surgery.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$2.96B

$2.81B

5.3%

Net income²

$126M

$91M

38.5%

Diluted EPS³

$0.24

$0.18

33.3%

_¹ Reported as “Net sales”. ² Reported as “Net income (loss) attributable to Baxter stockholders”. ³ Reported as “Diluted earnings per share”._

**Business Highlights**

-   Revenue growth was driven by Infusion Therapies and Advanced Surgery volume gains; Advanced Surgery rose about 12% in the quarter.
-   Reporting was reorganized to two segments with Pharmaceuticals folded into Infusion Therapies & Platforms.
-   Launched a new operating model, the Baxter Growth & Performance system, alongside enterprise transformation initiatives.
-   Supply constraints and a Novum LVP distribution hold weighed on pump and injectables volumes despite overall sales gains.

Original SEC Filing: BAXTER INTERNATIONAL INC \[ BAX \] - 10-Q - Jul. 30, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BAX.US](https://longbridge.com/en/quote/BAX.US.md)

## Related News & Research

- [Baxter (BAX) Stock May Be 25% Undervalued As Q2 Outlook Improves](https://longbridge.com/en/news/295087251.md)
- [Baxter launches USD 500 million cash tender offers for four note series](https://longbridge.com/en/news/294824953.md)
- [Baxter International Sees Unusually Large Options Volume (NYSE:BAX)](https://longbridge.com/en/news/294716272.md)
- [Baxter interim CFO Anita Zielinski resigns, effective Sept. 15](https://longbridge.com/en/news/294878516.md)
- [07:24 ETLUX Infusion Acquires Infuse IQ, Expanding Its National Ambulatory Infusion Footprint](https://longbridge.com/en/news/295098696.md)